BIOBANK Renal Transplantation University Hospitals Leuven

This study is currently recruiting participants.
Verified March 2014 by Universitaire Ziekenhuizen Leuven
Sponsor:
Information provided by (Responsible Party):
Prof Dr Maarten Naesens, Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier:
NCT01331668
First received: April 6, 2011
Last updated: March 25, 2014
Last verified: March 2014
  Purpose

This study aims to maintain a prospective biobank of human samples obtained from donors and recipients of renal allografts, including biopsy tissue, peripheral blood samples and urine samples.


Condition
Kidney Failure

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Biobank Renal Transplantation University Hospitals Leuven

Resource links provided by NLM:


Further study details as provided by Universitaire Ziekenhuizen Leuven:

Primary Outcome Measures:
  • Renal allograft survival [ Time Frame: 50 years after transplantation ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Biopsy material (tissue, RNA, DNA) Peripheral blood samples (serum, plasma, RNA, DNA) Urine samples


Estimated Enrollment: 5000
Study Start Date: March 2004
Estimated Study Completion Date: December 2099
Estimated Primary Completion Date: December 2099 (Final data collection date for primary outcome measure)
Groups/Cohorts
renal allograft donors and recipients
All de novo renal allograft recipients transplanted at the University Hospitals Leuven

Detailed Description:

Clinical data and bio-specimens are prospectively collected and stored for undefined future translational research projects.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

All donors and recipients of a kidney transplant at the University Hospitals Leuven

Criteria

Inclusion Criteria:

  • renal transplant recipients/donors

Exclusion Criteria:

  • none
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01331668

Contacts
Contact: Maarten Naesens, MD, PhD 32 16344580 maarten.naesens@uzleuven.be

Locations
Belgium
Department of Nephrology and Renal Transplantation - University Hospitals Leuven Recruiting
Leuven, BE, Belgium, 3000
Contact: Maarten Naesens, MD, PhD    32 16344580    maarten.naesens@uzleuven.be   
Principal Investigator: Maarten Naesens, MD, PhD         
Principal Investigator: Dirk Kuypers, MD, PhD         
Sponsors and Collaborators
Universitaire Ziekenhuizen Leuven
Investigators
Principal Investigator: Maarten Naesens, MD, PhD University Hospitals Leuven
  More Information

Publications:

Responsible Party: Prof Dr Maarten Naesens, Prof. Dr. Maarten Naesens, Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier: NCT01331668     History of Changes
Other Study ID Numbers: TRA-UZL-BIOBANK-001
Study First Received: April 6, 2011
Last Updated: March 25, 2014
Health Authority: Belgium: Federal Agency for Medicines and Health Products, FAMHP

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on April 17, 2014